Exagen Inc.
XGN
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $183.1M
$7.58
▲ +0.53%
P/E
-9.24
Mkt Cap
$183.1M
52-Wk Range
$2.59–$12.23
52-Week Range
$2.59 - $12.23
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 22.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- High volatility (beta 2.1). Larger-than-normal price swings expected.
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+76.7% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying XGN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 4, 2026
Reported EPS of -$0.13 vs -$0.19 consensus (+32.1% surprise). Revenue of $19.9M vs $17.8M expected (+12.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+32.1%
Revenue trend · last 8Q
—
—
—
—
+38%
+22%
+12%
+16%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$12.5M
$13.7M
$15.5M
$17.2M
$17.2M
$16.6M
$17.3M
$19.9M
Margins · last 8Q
Gross
61.3%
Operating
-8.6%
Profit
-16.0%
Wall Street consensus
7 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: B. Riley · Aug 5, 2026
vs Industry
How XGN stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.